Latest Breaking News On - Global head of neurology development - Page 1 : comparemela.com

Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis Frexalimab met primary

France generalSally bainEva schaefer jansenTarik elgoutniErik wallstrCorentine driancourtSandrine guendoulFelix lauscherNathalie phamGavin giovannoniQueen mary university of londonConsortium of multiple sclerosis centersGlobal head of neurology developmentLondon school of medicineBlizard instituteImmunext inc